PDT with immunotherapy and chemo for head and neck cancer
Part of Cancer clinical trials.
This trial tests a combination of an immunotherapy drug (toripalimab) and two chemotherapy drugs (cisplatin and docetaxel) as a first treatment before surgery or radiation for advanced head and neck cancers. It may help shrink tumors that can't be easily treated with standard therapy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a new diagnosis of squamous cell carcinoma (a type of head and neck cancer) in the mouth, throat, voice box, nose, or sinuses, or in an unknown spot.
- Your cancer is at a certain stage: stage III or IV (non-metastatic) if not linked to HPV, or stage II or III if linked to HPV.
- Your doctor thinks you could benefit from induction therapy (treatment before the main treatment) because of your tumor size, growth rate, symptoms, or need to shrink it.
- Your cancer has a CPS score of 1% or higher (a measure of a protein on cancer cells that helps immunotherapy work).
- You are 18 or older, can care for yourself (ECOG 0 or 1), and have adequate organ function (kidney, liver, blood counts).
- You are not pregnant, agree to use contraception, and have not had certain prior treatments like radiation to the head/neck or strong drug interactions.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of three immunotherapy drugs (PD-L1 t-haNK, NAI IL-15sa, and cetuximab) for people with head and neck squamous cell carcinoma that has spread or cannot be cured. The goal is to see if this treatment can shrink tumors or slow the disease.
This trial tests a combination of chemotherapy and an immunotherapy drug called Toripalimab before surgery for certain head and neck cancers. The goal is to see if this approach can reduce the extent of treatment needed while still being effective.
This trial tests a combination of an immunotherapy drug (tirelizumab) with two chemotherapy drugs before surgery for head and neck cancer that has spread to lymph nodes. The goal is to shrink the tumor and improve treatment outcomes.
This trial tests toripalimab (an immunotherapy) given before surgery for untreated head and neck squamous cell carcinoma, either alone or with chemotherapy. The goal is to shrink or control the cancer earlier and see if it improves outcomes for people who plan curative surgery.
This study tests whether adding an immunotherapy drug (toripalimab) to chemotherapy before surgery can help shrink tumors and improve outcomes for patients with locally advanced head and neck cancer. It aims to see if this combination is better than surgery alone or surgery with chemotherapy.
This trial tests a sequence of two drugs, toripalimab (an immunotherapy that helps your immune system fight cancer) and paclitaxel (a chemotherapy drug), for people with head and neck cancer that has spread or cannot be cured. It is designed for patients who have a lower level of physical function (ECOG score of 2) and aims to see if this treatment can help them.
Hear when a new Squamous Cell Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.